Unabsorbed Polylactide Adhesion Barrier Mimicking Recurrence of Gynecologic Malignant Diseases with Increased ¹⁸F-FDG Uptake on PET/CT
Overview
Affiliations
Purpose: To evaluate the incidence and characteristics of the unabsorbed polylactide adhesion barrier with increased (18)F-fluorodeoxyglucose ((18)F-FDG) uptake after surgeries for gynecologic malignancies.
Methods: Between September 2006 and November 2009, we reviewed the charts of 75 patients who were provided a polylactide adhesion barrier after surgery for gynecologic malignant diseases. We surveyed the cases of increased (18)F-FDG uptake on positron emission tomography/computed tomography (PET/CT), and evaluated the effectiveness of polylactide adhesion barrier using an adhesion scoring system.
Results: Ten patients (13.3 %) had a solitary pelvic mass with increased (18)F-FDG uptake in the follow up PET/CT. The characteristics of patients and tumors are described below. The median age was 48 years (range 19-66 years). The median tumor size was 1.9 cm (range 1.0-2.3 cm), and the median SUVmax of the pelvic mass was 5.1 (range 3.7-7.9). The median time between initial operations and second operation was 13.5 months (range 8-23 months). We performed laparoscopic excision of the pelvic mass, and the biopsy revealed foreign body reactions with the exception of 1 case, which contained tumor cells under the unabsorbed polylactide adhesion barrier. The median adhesion grade was 1 (range 0-2).
Conclusions: A solitary pelvic mass found in the PET/CT with increased (18)F-FDG uptake after usage of a polylactide adhesion barrier may be an unabsorbed remnant. The adhesion barrier should be used with caution in patients with gynecologic malignant diseases.
Immunometabolic cues recompose and reprogram the microenvironment around implanted biomaterials.
Maduka C, Schmitter-Sanchez A, Makela A, Ural E, Stivers K, Pope H Nat Biomed Eng. 2024; 8(10):1308-1321.
PMID: 39367264 DOI: 10.1038/s41551-024-01260-0.
Polylactide Degradation Activates Immune Cells by Metabolic Reprogramming.
Maduka C, Alhaj M, Ural E, Habeeb O, Kuhnert M, Smith K Adv Sci (Weinh). 2023; 10(31):e2304632.
PMID: 37737614 PMC: 10625072. DOI: 10.1002/advs.202304632.
Nakajo M, Jinguji M, Tani A, Yano E, Hoo C, Hirahara D Abdom Radiol (NY). 2021; 47(2):838-847.
PMID: 34821963 DOI: 10.1007/s00261-021-03350-y.
Nakajo M, Jinguji M, Tani A, Kikuno H, Hirahara D, Togami S Mol Imaging Biol. 2021; 23(5):756-765.
PMID: 33763816 DOI: 10.1007/s11307-021-01599-9.
Wang Y, Han R, Wang Q, Zheng J, Lin C, Lu C Int J Gen Med. 2021; 14:347-356.
PMID: 33568935 PMC: 7868188. DOI: 10.2147/IJGM.S287506.